The Evolution of Tafenoquine—Antimalarial for a New Millennium?

Snow RW , Craig MH , Deichmann U , le Sueur D. A preliminary continental risk map for malaria mortality among African children. Parasitol Today 1999; 15: 99–104.

Russell PF. Man's Mastery of Malaria. London: Oxford University Press, 1995.

Guttmann P , Ehrlich P. Ueber die Wirkung des Methylenblau bei Malaria. Berliner Klin Wochenschr 28 September 1891; No. 39: 953–6.

Couto M. Les injections endo-veineuses du bleu de méthylène dans la paludisme. Bull Soc Pathol 1908; 1: 292–5.

Werner H. Das Ehrlich-Hata Mittel 606 bei Malaria. Deutsche Med Wochenschr 1910; 36: 1792–4.

Schulemann W. Synthetic anti-malarial preparations. Proc R Soc Med 1932; 25: 897–905.

Steck EA. The Chemotherapy of Protozoan Diseases, Vol. III, Sections 4–5. Washington, DC: US Government Printing Office, 1972: 23. 128–23. 162.

Hörlein H. Über die chemischen Grundlagen und die Entwicklungs-Geschichte des Plasmochins. Arch Schiffs-Tropenhyg 1926; 30(suppl. 3): 305–10.

Roehl W. Die Wirkung des Plasmochins auf die Vogelmalaria. Arch Schiffs-Tropenhyg 1926; 30(suppl. 3): 311–18.

Carson PE. 8-Aminoquinolines. In: Peters W , Richards WHG , eds Antimalarial Drugs II. Current Antimalarials and New Drug Developments. Berlin: Springer-Verlag, 1984: 83–121.

Anonymous. A drug which prevents malaria [Editorial]. Lancet 1931; i: 1248–9.

Coatney GR , Cooper WC , Eddy NB , Greenberg J. Survey of Antimalarial Agents, Public Health Monograph No. 9. Washington, DC: US Government Printing Office, 1953.

Collins WE , Jeffrey GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1966; 55: 243–9.

Schmidt LH , Genther CS. The antimalarial properties of 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine (Daraprim). J Pharmacol Exper Ther 1953; 107: 61–91.

Elderfield RC , Mertel HE , Mitch RT , Wempen IM , Werbel E. Synthesis of primaquine and certain of its analogs. J Am Chem Soc 1955; 77: 4816–19.

Thompson PE , Werbel LM. Antimalarial Agents, Chemistry and Pharmacology. New York: Academic Press, 1972: 107–8.

Edgcomb JH , Arnold J , Young EH Jr , Alving AS , Eichelberger J. Primaquine, SN-13,272, a new curative agent in vivax malaria: A preliminary report. J Nat Malaria Soc 1950; 9: 285–92.

Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Org 1981; 59: 391–5.

Coleman RE , Clavin AM , Milhous WK. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes. Am J Trop Med Hyg 1992; 46: 169–82.

Terzian LA , Stahler N , Dawkins AT Jr. The sporogonous cycle of Plasmodium vivax in Anopheles mosquitoes as a system for evaluating the prophylactic and curative capabilities of potential antimalarial compounds. Exp Parasitol 1968; 23: 56–66.

Butcher GA. Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 1997; 27: 975–87.

Peters W. Chemotherapy and Drug Resistance in Malaria, Vols. 1 and 2. London: Academic Press, 1987.

Alving AS , Johnson CF , Tarlow AR , Brewer GJ , Kellermeyer RW , Carson PE. Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimes of drug administration. Bull World Health Org 1960; 22: 621–31.

Arnold J , Alving AS , Hockwald RS The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 1955; 46: 391–7.

Arnold J , Alving AS , Clayman CB , Hochwald RS. Induced primaquine resistance in vivax malaria. Trans R Soc Trop Med Hyg 1961; 55: 345–50.

Powell RD , Brewer GJ. Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg 1967; 16: 693–8.

Carson PE , Hohl R , Nora MV , Parkhurst GW , Ahmad T , Scanlan S , Frischer H. Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man. hull World Health Org 1981; 59: 427–37.

Davidson DE , Ager AL , Brown JL , Chappie FE , Whitmire RE , Rossan RN. New tissue schizontocidal antimalarial drugs. Bull World Health Org 1981; 59: 463–79.

Schuurkamp GJ , Spicer PE , Kereu RK , Bulungol PK. A mixed infection of vivax and falciparum malaria apparently resistant to 4-aminoquinoline: a case report. Trans R Soc Trop Med Hyg 1989; 83: 607–8.

Rieckmann KH , Davis DR , Hutton DC. Plasmodium vivax resistance to chloroquine? lancet 1989; ii: 1183–4.

Whitby M , Wood G , Veenendaal JR , Rieckmann KH. Chloroquine-resistant Plasmodium vivax. Lancet 1989; ii: 1395.

Baird JK , Basri H , Purnomo Resistance to chloroquine by Plasmodium vivax in Irian Jaya. Am J Trop Med Hyg 1991; 44: 547–52.

Pukrittayakamee S , Vanijanonta S , Chantra A , Clemens R , White NJ. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994; 169: 932–5.

Baird JK , Fryauff DJ , Basri H Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52: 479–84.

Fryauff DJ , Baird JK , Basri H Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346: 1190–3.

Weiss WR , Oloo AJ , Johnson A , Koech D , Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Inf Dis 1995; 171: 1569–75.

Baird JK , Basri H , Subianto B Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Inf Dis 1995; 171: 1678–82.

Peters W , Robinson BL , Milhous WK. The chemotherapy of rodent malaria. LI, Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 1993; 87: 547–52.

Brueckner RP , Lasseter KC , Lin ET , Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1988; 58: 645–9.

Brueckner RP , Coster T , Wesche DL , Shmuklarsky M , Schuster BG. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Ag Chemother 1998; 42: 1293–4.

Shanks D. Etaquine (WR 238605) for the prophylaxis of Plasmodium falciparum malaria. In: Symposium on etaquine held in Association with the Annual Meeting of the American Society of Tropical Medicine and Hygiene, Colorado Springs Report, Florida, 11 September 1997 [Abstract]. ASTMH, 1998.

Milhous WK. Preclinical efficacy of etaquine (WR 238605). In: Symposium on etaquine held in Association with Annual Meeting of the American Society of Tropical Medicine and Hygiene, Colorado Springs Resort, Florida, 11 December 1997 [Abstract]. ASTMH 1998.

Cooper RD , Milhous WK , Rieckmann KH. The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Trans R Soc Trop Med Hyg 1994; 88: 691–2.

Obaldia N , Rossan RN , Cooper RD WR 238605, chloroquine, and their combinations as blood schizontocides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys. Am J Trop Med Hyg 1997; 56: 508–10.

Walsh DS. Etaquine (WR 238605) for the prevention of relapse of Plasmodium vivax malaria. In: Symposium on Etaquine held in Association with Annual Meeting of the American Society of Tropical Medicine and Hygiene, Colorado Springs Resort, Florida, 11 December 1997 [Abstract]. ASTMH, 1998.

White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Ag Chemother 1997; 41: 1413–22.